Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Nuance Investments LLC

Nuance Investments LLC decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 47.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 164,683 shares of the medical equipment provider's stock after selling 148,184 shares during the quarter. Nuance Investments LLC owned 0.07% of Hologic worth $13,415,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Price T Rowe Associates Inc. MD lifted its holdings in Hologic by 77.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider's stock worth $490,931,000 after buying an additional 2,753,016 shares during the period. Swedbank AB purchased a new stake in shares of Hologic during the 1st quarter valued at $120,827,000. Black Creek Investment Management Inc. lifted its holdings in shares of Hologic by 60.9% during the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider's stock valued at $173,669,000 after purchasing an additional 885,524 shares during the last quarter. Mackenzie Financial Corp lifted its holdings in shares of Hologic by 1,023.3% during the 2nd quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider's stock valued at $66,506,000 after purchasing an additional 815,960 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Hologic during the 2nd quarter valued at $39,427,000. Institutional investors own 94.73% of the company's stock.

Hologic Price Performance

Hologic stock traded down $0.53 during midday trading on Wednesday, reaching $78.04. The company had a trading volume of 1,298,044 shares, compared to its average volume of 1,590,061. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The firm's fifty day simple moving average is $80.52 and its 200-day simple moving average is $78.30. Hologic, Inc. has a 12-month low of $67.59 and a 12-month high of $84.67. The company has a market capitalization of $18.13 billion, a P/E ratio of 23.44, a P/E/G ratio of 2.48 and a beta of 0.98.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts' consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same period last year, the company posted $0.89 EPS. The business's revenue was up 4.5% on a year-over-year basis. As a group, equities analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on HOLX shares. StockNews.com raised Hologic from a "hold" rating to a "buy" rating in a research report on Thursday, November 14th. Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 price target on shares of Hologic in a research report on Tuesday, October 15th. Leerink Partners cut their price target on Hologic from $95.00 to $90.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th. JPMorgan Chase & Co. increased their price target on Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Finally, Citigroup lowered shares of Hologic from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $95.00 to $85.00 in a research note on Tuesday, October 1st. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Hologic currently has a consensus rating of "Moderate Buy" and a consensus target price of $89.91.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.